| 摘要 |
The invention addresses the problem of providing an encapsulated formulation containing ravuconazole methyl phosphate, the formulation limiting the delay of elution that results from storage regardless of the amount of ravuconazole methyl phosphate filled. The invention provides an encapsulated formulation, which comprises a filling that contains {[(1R,2R)-2-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-1-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl methyl) propyl] oxy} methyl dihydrogen phosphate, a pharmacologically permissible salt thereof, or a solvate of any of same, and a capsule that does not contain gelatin. |
